We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

On drugs?

2 Dec 2014 By Robert Cyran

Otsuka’s $3.5 bln purchase of Avanir prolongs a track record of overpriced M&A for Japan’s pharmaceutical firms. Granted, the company needs new offerings before the patent expires next year on its blockbuster schizophrenia drug. But this transaction smacks of desperation.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)